



## APRIL 2022 REPORT

### CANNABIS FOR PARKINSON'S DISEASE

#### THE QUESTION

April is Parkinson's Disease Awareness Month.

How many patients are treating Parkinson's disease with cannabis, and what does this demographic look like?

#### FOR MORE INFORMATION CONTACT



68 34th Street Suite C642,  
Brooklyn, NY, 11232, USA



+1 917.210.0543



info@ryah.com



<https://ryahgroup.com/>

#### THE ANSWER

**Between January 18, 2018, and April 25, 2022, patients logged more than 1,570 sessions in the RYAH Data Ecosystem for Parkinson's disease.**

Slightly more men than women reported using cannabis for Parkinson's through RYAH Data.

Most patients had moderate experience with cannabis, reporting primarily from California, Oklahoma, and Florida.

Patients logged tens of thousands of sessions in RYAH for symptoms commonly associated with Parkinson's, including sleep issues, pain, and depression.

# 1,571

**SESSIONS LOGGED FOR PARKINSON'S DISEASE  
SINCE JANUARY 1, 2018**


## ANALYSIS

In 2022, the Journal of Cannabis Research published “Cannabinoids in the management of behavioral, psychological, and motor symptoms of neurocognitive disorders,” a systematic review. The authors included 11 studies in their final review.


The review determined that cannabis-based medicines improve non-motor symptoms (falls, depression, pain, and sleep disturbances).

This systemic report found ‘good’ and ‘fair’ evidence that pharmaceutical cannabinoids are effective “in relief from agitation in the context of dementia” relevant to Parkinson’s disease. [1]

## GENDER




## CANNABIS EXPERIENCE



## LOCATION

### BY STATE



## ANALYSIS


A survey on cannabis use among people living with Parkinson's disease in the US published in 2021 sought to find out if people were using cannabis as a treatment, and what they experienced.

With more than 1,000 respondents, the authors discovered that 24.5 percent of respondents had used cannabis in the last six months.

Of those who used medical cannabis, the majority did so strictly to relieve their Parkinson's symptoms. Approximately 45 percent used it to calm anxieties, 44 percent to treat pain, and 44 percent for sleep issues. [2]

## AILMENTS

TREATED IN CONJUNCTION WITH PARKINSON'S



## General Satisfaction and Overall Effectiveness of Medical Cannabis

"MOST OF THE PATIENTS (37/45, 82.2%) REPORTED THAT [MEDICAL CANNABIS] IMPROVED THEIR OVERALL SYMPTOMS, 2 REPORTED NO DIFFERENCE (4.4%), AND 6 (13.3%) REPORTED FEELING WORSE."

– 2017 Survey of 47 Israeli Parkinson's Patients [3]

## SYMPTOMS OF PARKINSON'S

ASSOCIATED SYMPTOMS TREATED WITH CANNABIS IN RYAH



## ADDITIONAL SOURCES

[1] Bahji, A., Breward, N., Duff, W. et al. Cannabinoids in the management of behavioral, psychological, and motor symptoms of neurocognitive disorders: a mixed studies systematic review. *J Cannabis Res* 4, 11 (2022). <https://doi.org/10.1186/s42238-022-00119-y>

[2] Feeney, Megan P et al. "Weeding through the haze: a survey on cannabis use among people living with Parkinson's disease in the US." *NPJ Parkinson's disease* vol. 7,1 21. 3 Mar. 2021, doi:10.1038/s41531-021-00165-y

[3] Balash, Y., Bar-Lev Schleider, L., Korczyn, A. D., Shabtai, H., Knaani, J., Rosenberg, A., Baruch, Y., Djaldetti, R., Giladi, N., & Gurevich, T. (2017). Medical cannabis in parkinson disease: Real-life patients' experience. *Clinical Neuropharmacology*, 40(6), 268-272. <https://doi.org/10.1097/wnf.0000000000000246>

### FOR MORE INFORMATION CONTACT

 68 34th Street Suite C642,  
Brooklyn, NY, 11232, USA

 +1 917.210.0543

 [info@ryah.com](mailto:info@ryah.com)

 <https://ryahgroup.com/>

## DISCLAIMER

This Report is intended to be used strictly for informational purposes only and is not intended to constitute, or be a substitute for, medical advice and should not be relied upon in any such regard. Readers are strongly urged to consult a qualified healthcare professional and conduct independent research in respect of any questions regarding the information set out in the Report. This Report does not reflect all available scientific research on the subject matter of this Report and is not intended as an exhaustive resource. It is also possible that other relevant scientific findings (including conflicting findings) may have been reported since the date of this Report or of the information referred to herein. Accordingly, RYAH Medtech Inc. and its associated and affiliated companies (collectively, the "RYAH Group") assume no responsibility for omissions or incomplete information in this Report.

The inclusion of any third party reference in this Report is not intended to be, and should not be construed as, an endorsement of such third party resource or of the treatments, programs or other information discussed therein. Although reasonable care has been taken in the preparation of the information contained in this Report, such information is provided on an "as-is" basis. None of the members of the RYAH Group make, in any manner, any representation, warranty, guarantee, or condition, whether express, or implied, statutory or otherwise, as to the information's quality, accuracy, currency, completeness, or reliability.

The RYAH Group shall not be responsible for, and shall have no liability, whether direct, indirect, consequential, contingent, special, or incidental, related to or arising from the information in the Report or the use (or misuse) thereof, under any theory of liability and even if advised of the possibility thereof. Anyone using the information in the Report does so at their own risk, and by using such information, agrees to indemnify each member of the RYAH Group and its content providers and directors and officers from any and all liability, loss, damages, costs, and expenses (including legal fees and expenses) arising from such person's use of the information in the Report.